Ultragenyx Receives PRIME Designation From European Medicines Agency For GTX-102 For Angelman Syndrome
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical Inc. has received PRIME designation from the European Medicines Agency (EMA) for GTX-102, a therapeutic candidate for Angelman Syndrome. This marks the first time a treatment for Angelman Syndrome has received such designation. The Phase 1/2 study for GTX-102 is fully enrolled, with expansion data anticipated in the first half of 2024.
February 05, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical Inc. (RARE) has been granted PRIME designation by the EMA for its Angelman Syndrome treatment, GTX-102, marking a significant regulatory milestone.
The PRIME designation by the EMA for GTX-102 is a significant positive development for Ultragenyx, indicating a high level of support and recognition from regulatory authorities. This could potentially accelerate the drug's approval process and market entry, positively impacting Ultragenyx's stock in the short term. The anticipation of expansion data in the first half of 2024 further adds to the positive outlook, as successful results could lead to increased investor confidence and stock price appreciation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90